Review




Structured Review

Nissui Pharmaceutical xp4pasv
Xp4pasv, supplied by Nissui Pharmaceutical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/xp4pasv/product/Nissui Pharmaceutical
Average 90 stars, based on 1 article reviews
xp4pasv - by Bioz Stars, 2026-03
90/100 stars

Images



Similar Products

90
Nissui Pharmaceutical xp4pasv
Xp4pasv, supplied by Nissui Pharmaceutical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/xp4pasv/product/Nissui Pharmaceutical
Average 90 stars, based on 1 article reviews
xp4pasv - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Nissui Pharmaceutical sv40-transformed human skin fibroblast cell line xp4pasv
Schematic diagram of the intracellular TLS assay using a shuttle vector. dG, dfG, and GA-FAPy-dfG were introduced at a specific position (denoted as X) on one side of the shuttle vector (modified strand), whereas the other strand (unmodified strand) had a three-base mismatch ( underlined ) for the GA-FAPy-dfG and SmiI recognition sequence ( blue box ). The vector was transfected into <t>XP4PASV</t> cells and allowed to replicate for 48 h. Progeny plasmids were then recovered and digested with DpnI to remove nonreplicated original DNA. Escherichia coli was transformed with progeny plasmids, and resultant clones were subjected to PCR to amplify the lesion site. The PCR products were treated with SmiI to digest unmodified strand progeny. Replication efficiency was calculated from the ratio of the modified strand progeny in the recovered plasmids and is shown relative to dG. Mutation spectra were analyzed using Sanger sequencing of the PCR products of the modified strand progeny. GA-FAPy-dfG, N 6 -(2-deoxy-2-fluoro- d -arabinofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-5-[ N -(2-carbamoyl-2-hydroxyethyl)formamido]pyrimidine; TLS, translesion DNA synthesis.
Sv40 Transformed Human Skin Fibroblast Cell Line Xp4pasv, supplied by Nissui Pharmaceutical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sv40-transformed human skin fibroblast cell line xp4pasv/product/Nissui Pharmaceutical
Average 90 stars, based on 1 article reviews
sv40-transformed human skin fibroblast cell line xp4pasv - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Coriell Institute for Medical Research sv40-transformed xp4pasv-eb fibroblasts deficient in xpc (gm15983)
Schematic diagram of the intracellular TLS assay using a shuttle vector. dG, dfG, and GA-FAPy-dfG were introduced at a specific position (denoted as X) on one side of the shuttle vector (modified strand), whereas the other strand (unmodified strand) had a three-base mismatch ( underlined ) for the GA-FAPy-dfG and SmiI recognition sequence ( blue box ). The vector was transfected into <t>XP4PASV</t> cells and allowed to replicate for 48 h. Progeny plasmids were then recovered and digested with DpnI to remove nonreplicated original DNA. Escherichia coli was transformed with progeny plasmids, and resultant clones were subjected to PCR to amplify the lesion site. The PCR products were treated with SmiI to digest unmodified strand progeny. Replication efficiency was calculated from the ratio of the modified strand progeny in the recovered plasmids and is shown relative to dG. Mutation spectra were analyzed using Sanger sequencing of the PCR products of the modified strand progeny. GA-FAPy-dfG, N 6 -(2-deoxy-2-fluoro- d -arabinofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-5-[ N -(2-carbamoyl-2-hydroxyethyl)formamido]pyrimidine; TLS, translesion DNA synthesis.
Sv40 Transformed Xp4pasv Eb Fibroblasts Deficient In Xpc (Gm15983), supplied by Coriell Institute for Medical Research, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sv40-transformed xp4pasv-eb fibroblasts deficient in xpc (gm15983)/product/Coriell Institute for Medical Research
Average 90 stars, based on 1 article reviews
sv40-transformed xp4pasv-eb fibroblasts deficient in xpc (gm15983) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Schematic diagram of the intracellular TLS assay using a shuttle vector. dG, dfG, and GA-FAPy-dfG were introduced at a specific position (denoted as X) on one side of the shuttle vector (modified strand), whereas the other strand (unmodified strand) had a three-base mismatch ( underlined ) for the GA-FAPy-dfG and SmiI recognition sequence ( blue box ). The vector was transfected into XP4PASV cells and allowed to replicate for 48 h. Progeny plasmids were then recovered and digested with DpnI to remove nonreplicated original DNA. Escherichia coli was transformed with progeny plasmids, and resultant clones were subjected to PCR to amplify the lesion site. The PCR products were treated with SmiI to digest unmodified strand progeny. Replication efficiency was calculated from the ratio of the modified strand progeny in the recovered plasmids and is shown relative to dG. Mutation spectra were analyzed using Sanger sequencing of the PCR products of the modified strand progeny. GA-FAPy-dfG, N 6 -(2-deoxy-2-fluoro- d -arabinofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-5-[ N -(2-carbamoyl-2-hydroxyethyl)formamido]pyrimidine; TLS, translesion DNA synthesis.

Journal: The Journal of Biological Chemistry

Article Title: A formamidopyrimidine derivative from the deoxyguanosine adduct produced by food contaminant acrylamide induces DNA replication block and mutagenesis

doi: 10.1016/j.jbc.2023.105002

Figure Lengend Snippet: Schematic diagram of the intracellular TLS assay using a shuttle vector. dG, dfG, and GA-FAPy-dfG were introduced at a specific position (denoted as X) on one side of the shuttle vector (modified strand), whereas the other strand (unmodified strand) had a three-base mismatch ( underlined ) for the GA-FAPy-dfG and SmiI recognition sequence ( blue box ). The vector was transfected into XP4PASV cells and allowed to replicate for 48 h. Progeny plasmids were then recovered and digested with DpnI to remove nonreplicated original DNA. Escherichia coli was transformed with progeny plasmids, and resultant clones were subjected to PCR to amplify the lesion site. The PCR products were treated with SmiI to digest unmodified strand progeny. Replication efficiency was calculated from the ratio of the modified strand progeny in the recovered plasmids and is shown relative to dG. Mutation spectra were analyzed using Sanger sequencing of the PCR products of the modified strand progeny. GA-FAPy-dfG, N 6 -(2-deoxy-2-fluoro- d -arabinofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-5-[ N -(2-carbamoyl-2-hydroxyethyl)formamido]pyrimidine; TLS, translesion DNA synthesis.

Article Snippet: XP4PASV, an SV40-transformed human skin fibroblast cell line from an XPC patient, was cultured in Dulbecco’s modified Eagle’s medium (Nissui Pharmaceutical) supplemented with 10% fetal bovine serum, at 37 °C and 5% CO 2 .

Techniques: Plasmid Preparation, Modification, Sequencing, Transfection, Transformation Assay, Clone Assay, Mutagenesis, DNA Synthesis